Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.

Details

Language :

English

ISSN :

0732183X

Volume :

42

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

174954432

Full Text :

https://doi.org/10.1200/JCO.2024.42.3_suppl.330